Pamela (Pam) Demain serves as the interim Chief Business Officer of Adagene. She has over 30 years of experience in pharmaceutical corporate development and licensing. Most recently she served as VP of Business Development at The Medicines Company, up through their sale to Novartis in November 2019. Previously, she served as Executive Director, Corporate Licensing at Merck for 15 years. In that role, she was responsible for negotiating transactions with companies, universities and institutions worldwide. Prior to that, she was in charge of the Business Information & Research Department in the Worldwide Human Health Marketing area. Earlier positions included 13 years in Corporate Planning, Marketing Communications and Product Management at Merck. Ms. Demain’s career began in the natural products laboratory of Gruppo Lepetit, an Italian pharmaceutical company, which was then a subsidiary of the Dow Chemical.
Ms. Demain served as the President of the Licensing Executives Society (LES) USA and Canada during 2014 – 2015. She is a graduate of the University of Massachusetts at Amherst, and holds a M.B.A. in International Business from The American University in Washington, D.C. and is a Certified Licensing Professional (CLP).